https://pubmed.ncbi.nlm.nih.gov/38114742
This study demonstrates that patient-derived intestinal organoids and tumors can be used with immune cells to predict the toxicity of T-cell-engaging bispecific antibodies, revealing clinical toxicities and inter-patient variability not seen in conventional models.